Navigation Links
CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that posters related to its oncology research efforts will be presented at the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007 in Los Angeles, CA.

"Systematic Screening of Targeted Chemical Combinations for Cancer Therapy", Heilbut, (Abstract #1410) will be presented on Sunday, April 15, 1-5pm PT and "Synergistic Enhancers of TRAIL-Mediated Apoptosis: A Quantitative Parallel Comparison of TRAIL-Small Molecule Synergies using cHTS(TM)", Short, (Abstract #4873) will be presented on Tuesday, April 17, 1-5pm PT.

About cHTS(TM)

To discover combinations of molecules that exhibit novel patterns of activity against disease networks, CombinatoRx, Incorporated uses its combination High Throughput Screening (cHTS(TM)) drug discovery platform. Using this proprietary platform, the company systematically searches millions of combinations across a large portfolio of phenotypic disease models, identifying patterns of activity against both known and novel targets in a broad range of disease areas. Each combination is evaluated to quantify and visualize its activity at a range of dose ratios. Combinations with synergistic therapeutic effects against disease phenotypes are flagged automatically using a custom-designed informatics backbone, then profiled to further determine their mechanism of action and product suitability. Innovations in computational biology techniques and software design automate the CombinatoRx process, enabling the company to search large numbers of combinations and rapidly select candidates with desirable patterns of activity.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going bey ond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its drug discovery technology, its product candidates and their clinical potential, its plans for clinical development of its product candidates and its business plans. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, assumptions regarding the mechanism of action of our product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statemen ts. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2007 CombinatoRx, Incorporated. All rights reserved.


CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
Executive Vice President, Chief Financial Officer
Fax: 617-301-7010
Gina Nugent, 617-301-7099
VP, Corporate Communications and IR
Fax: 617-301-7010


Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
5. The Past, Present and Future of HLA Typing
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/30/2015)... 2015 North America was ... grow at a CAGR of 7.6% from 2015 to 2020. ... 135.6 million in 2014, and is expected to grow at a ... to the new Market Research Report "North America Cardiac Output Monitoring ... (Hospitals, ambulatory care, others) - Analysis And Forecast To 2020", the ...
(Date:11/30/2015)... --> --> ... by Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application ... Geography - Global Forecast to 2020", published by MarketsandMarkets, is ... CAGR of 5.2% during the forecast period from 2015 to ... 62 Figures spread through 167 P ages and in-depth ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Foundation (Meso Foundation) released information for caregivers and held two webinars on topics ... available on demand free of charge at . , With a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill ... fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and ... is also located in Battle Creek, joined in for this campaign that sought to ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the week of ... raise funds for its research, education, support, and advocacy efforts. The campaign is ... , The Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds ...
Breaking Medicine News(10 mins):